Cogent Biosciences, Inc.
COGT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $822 | $679 | $862 |
| - Cash | $125 | $128 | $126 | $98 |
| + Debt | $59 | $61 | $17 | $17 |
| Enterprise Value | – | $755 | $570 | $781 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$1 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$79 | -$72 | -$74 | -$73 |
| % Margin | – | – | – | – |
| Net Income | -$81 | -$74 | -$72 | -$68 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.71 | -0.64 | -0.52 | -0.61 |
| % Growth | -10.9% | -23.1% | 14.8% | – |
| Operating Cash Flow | -$64 | -$55 | -$67 | -$61 |
| Capital Expenditures | -$0 | -$0 | -$1 | -$0 |
| Free Cash Flow | -$64 | -$55 | -$67 | -$61 |